Hepatitis c virus hcv infection is the most common indication for liver transplantation in north america and europe while hepatitis c recurrence is common after transplantation 5 year graft and patient survival in hcv infected patients are similar to those of patients transplanted for other chronic liver diseases with longer periods of follow up the proportion of patients with fibrosis or cirrhosis increases and graft loss does occur because of recurrent disease both viral and host . Hepatitis c virus and liver transplantation is designed to provide a comprehensive and state of the art overview of the major issues specific to the field of liver transplantation and hepatitis c virus infection the sections of the book have been structured to review the overall scope of issues of recurrent hepatitis c in different complex settings including retransplantation hiv coinfected patients or in the setting of suboptimal graft donors this book provides up to date information on . Hepatitis c virus hcv is a major cause of death from infectious disease and is still the leading indication for liver transplantation in the united states and other western countries all oral direct acting antiviral daa therapies have revolutionized the field with hcv cure rates of more than 90 among treated patients the safety and tolerability of these daa agents have expanded the feasibility of hcv treatment even in the challenging pre and post liver transplant settings however . Hepatitis c virus hcv infection remains the most common cause of hepatic failure requiring orthotopic liver transplantation and the disparity between the number of patients in need of liver replacement and the number of organs available continues to grow unfortunately without viral eradication before transplantation hcv recurrence is universal and is associated with poor graft and patient survival despite expansion of the donor pool and attempts to suppress hcv activity with various